Effect of Myoinositol and Metformin in combination on clinical and hormonal profile in patients of polycystic ovarian syndrome

Simple item page
dc.contributor.authorNagaria, Triptien_US
dc.contributor.authorMohapatra, Arpitaen_US
dc.contributor.authorJaiswal, Jyotien_US
dc.date.accessioned2020-10-16T07:53:31Z
dc.date.available2020-10-16T07:53:31Z
dc.date.issued2019-02
dc.description.abstractBackground: Polycystic ovarian syndrome (PCOS) also known as hyperandrogenic anovulation syndrome or Stein – Leventhal syndrome is an endocrine disorder, characterized by anovulation, oligomenorrhea, amenorrhea, features of androgenic hormone excess (hirsutism, acne, alopecia, seborrhea) and insulin resistance. The global prevalence ranges from 2.2% to 26%. Methods: A prospective observational study was conducted from December 2015 to December 2016 in Department of Obstetrics and Gynecology at Pt. Jawahar Lal Nehru Memorial medical college and associated Dr. Bhim Rao Ambedkar memorial hospital, Raipur (C.G.) after obtaining permission of ethical committee of the institute to evaluate the effect of myoinositol and metformin on clinical profile in patients of polycystic ovarian syndrome. 70 women were included in the study who received a combination of myoinositol 600mg and metformin 500mg (twice a day) for 3 months for the management of PCOS. Prior to the start of the therapy, a detailed history and baseline investigations were recorded. Cases were reassessed at the end of three months of therapy for evaluation of change in clinical and hormonal profile.Results: 90.09% (63/70) cases showed improvement in the menstrual complaints. Spontaneous onset of menses occurred in all the cases presented with amenorrhea, in nearly 90% within 2 months of start of treatment. Regularization of cycles was observed in nearly 50% of patients with infrequent menses. Amongst all the cases with cutaneous manifestations, maximum improvement was seen in cases of acne (4/6) i.e. 66.66%. 25% (5/20) patients with infertility conceived during the study period.Conclusions: Myoinositol with metformin in combination has resulted in significant improvement in the clinical profile with reduction in individual drug dosage in cases with PCOS.en_US
dc.identifier.affiliationsDepartment of Obstetrics and Gynecology, Pt. JNM Medical College, Raipur, Chhattisgarh, Indiaen_US
dc.identifier.citationNagaria Tripti, Mohapatra Arpita, Jaiswal Jyoti. Effect of Myoinositol and Metformin in combination on clinical and hormonal profile in patients of polycystic ovarian syndrome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2019 Feb; 8(2): 702-709en_US
dc.identifier.issn2320-1770
dc.identifier.issn2320-1789
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/206473
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber2en_US
dc.relation.volume8en_US
dc.source.urihttps://dx.doi.org/10.18203/2320-1770.ijrcog20190309en_US
dc.subjectMetforminen_US
dc.subjectMyoinositolen_US
dc.subjectPCOSen_US
dc.titleEffect of Myoinositol and Metformin in combination on clinical and hormonal profile in patients of polycystic ovarian syndromeen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrcog2019v8n2p702.pdf
Size:
347.02 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Reproduction, Contraception, Obstetrics and Gynecology